NU-9 stoppt die Alzheimer-Krankheit im Tiermodell, bevor Symptome auftreten: „Studie deckt einen neuen Alzheimer-Auslöser auf – und einen Weg, sie zu stoppen.“ »
https://news.northwestern.edu/stories/2025/12/nu-9-halts-alzheimers-disease-in-animal-model-before-symptoms-begin
4 Kommentare
« Alzheimer’s disease begins decades before its symptoms appear, with early events like toxic amyloid beta oligomers accumulating inside neurons and glial cells becoming reactive long before memory loss is apparent. By the time symptoms emerge, the underlying pathology is already advanced. This is likely a major reason many clinical trials have failed. They start far too late. In our study, we administered NU-9 before symptom onset, modeling this early, pre-symptomatic window. »
Reference: Kranz DL, de Leon Velez O, Ulupinar E, Ozdinler PH, Silverman RB, Klein WL. Identification of a glia-associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU-9. Alzheimer’s Dement. 2025; 21:e70968. https://doi.org/10.1002/alz.70968
If the amyloid was the cause then removing it should lead to the halting of disease progression in already affected individuals. That doesn’t seem to be the case with all the other amyloid focused treatments. Based on that I’m skeptical beta amyloid plays the key role in pathogenesis of Alzheimer’s. If anything beta amyloid is found in people without Alzheimer’s and it’s hypothesized to be part of normal aging (albeit in much lower levels than in Alzheimer’s).
when can we expect alzheimers patients to have access to this drug?